Executive Summary
HHS awarded Amgen a $774M (potential $917M) 10-year BARDA contract for biotech R&D targeting thrombocytopenia in mass casualty events, with $712M already outlayed signaling strong federal commitment to biodefense. This provides Amgen stable long-term revenue amid full competition win as a large biotech player. Investors should monitor front-loaded spending risks and $143M unobligated options for upside.
Tracking the trend? Catch up on the prior All HHS Contracts digest from March 06, 2026.
Investment Signals(1)
- Amgen secures massive 10-year BARDA R&D award(HIGH)▲
$774M obligation ($712M outlayed) for thrombocytopenia treatment ensures predictable federal revenue through 2032.
Risk Flags(3)
- Execution[HIGH RISK]▼
Firm fixed price terms expose Amgen to cost overruns over 10-year horizon
- Regulatory[HIGH RISK]▼
Long-term health R&D faces execution and approval uncertainties
- Market[MEDIUM RISK]▼
High front-loaded outlays ($712M of $774M) may limit back-end revenue
Opportunities(2)
- ◆
$143M unobligated options could boost revenue if exercised
- ◆
BARDA mass casualty focus positions Amgen for follow-on R&D contracts
Sector Themes(1)
- ◆
Single $774M HHS/BARDA award to large biotech underscores sustained investment in mass casualty countermeasures.
Watch List(1)
- 👁
{"entity"=>"Amgen BARDA contract (75A50122C00028)", "reason"=>"92% obligation outlayed with $143M options; tracks federal biotech revenue stability", "trigger"=>"Option exercises >$50M or outlay stagnation"}
Get daily alerts with 1 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC